Last updated: November 11, 2026
Drospirenone and ethinyl estradiol is a mature combined oral contraceptive market with extensive generic competition. The combination was commercialized in the United States through Bayer brands including Yasmin and Yaz, but core U.S. patent and regulatory exclusivity has expired. Current economics are driven by low-cost generic supply, pharmacy substitution, payer formularies, and product differentiation rather than molecule-level exclusivity.
The market remains commercially relevant because the product has broad contraceptive use and branded variants retain demand among patients seeking specific dosing regimens, tolerability profiles, or access through insurance. Product-level revenue is difficult to isolate because the active ingredients are sold under multiple brands and generic labels, while manufacturers generally report oral contraceptive revenue within broader women’s-health or pharmaceutical segments.
What is drospirenone and ethinyl estradiol used for?
Drospirenone and ethinyl estradiol is an oral combined hormonal contraceptive. Depending on the product label, approved or recognized uses include:
- Prevention of pregnancy.
- Treatment of moderate acne vulgaris in patients seeking oral contraception.
- Treatment of premenstrual dysphoric disorder in products with the relevant FDA indication.
Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is the estrogen component. The combination is available in 21-active-tablet and 24-active-tablet regimens, with different strengths and placebo-tablet configurations.
The FDA-approved indications are product-specific. A generic product generally relies on an abbreviated new drug application and must demonstrate bioequivalence to its reference listed drug, but its label can vary depending on the reference product and approved indications.
Which brands contain drospirenone and ethinyl estradiol?
The principal U.S. brands include Yasmin and Yaz, although current commercial ownership and distribution arrangements differ by market and product.
| Product or product family |
Typical formulation |
Original commercial association |
Market position |
| Yasmin |
Drospirenone 3 mg / ethinyl estradiol 0.03 mg |
Bayer |
Mature branded product |
| Yaz |
Drospirenone 3 mg / ethinyl estradiol 0.02 mg |
Bayer |
Mature branded product |
| Gianvi |
Drospirenone 3 mg / ethinyl estradiol 0.02 mg |
Genericized brand |
Former authorized-generic or branded-generic positioning |
| Nikki |
Drospirenone 3 mg / ethinyl estradiol 0.02 mg |
Generic manufacturers and marketers |
Branded generic |
| Ocella |
Drospirenone 3 mg / ethinyl estradiol 0.03 mg |
Genericized brand |
Branded generic |
| Multiple unbranded generics |
Several strengths and pack configurations |
Teva, Lupin, Viatris/Mylan, Glenmark and others over time |
Principal volume segment |
Commercial availability changes by country, manufacturer, supply status, and distributor. FDA-approved products should be assessed through the Drugs@FDA database and the Orange Book rather than through historical brand lists alone (U.S. Food and Drug Administration [FDA], n.d.-a, n.d.-b).
When did drospirenone and ethinyl estradiol lose exclusivity?
Core U.S. exclusivity has expired. Yasmin was approved in 2001, and Yaz was approved in 2006. Generic competition entered the U.S. market after patent and regulatory barriers were resolved.
The combination is therefore in a post-exclusivity phase:
| Milestone |
Approximate timing |
Commercial effect |
| Yasmin U.S. approval |
2001 |
Initiated U.S. branded market |
| Yaz U.S. approval |
2006 |
Added lower-estrogen, 24-day active-tablet product |
| Initial patent litigation and Paragraph IV activity |
Late 2000s to early 2010s |
Delayed or structured generic entry |
| First major generic launches |
Early 2010s |
Began price erosion |
| Broad generic availability |
2010s |
Shifted volume to low-price products |
| Current market |
2020s |
Mature, multi-supplier generic category |
The exact commercial entry date for each generic depended on litigation outcomes, settlement terms, product approval, and manufacturer strategy. Generic entry was not a single event because several applicants and product configurations entered at different times.
What patents protected Yasmin and Yaz?
The original patent estate protected the combination, dosage forms, and aspects of the contraceptive regimen. The principal intellectual-property categories were:
- Composition claims covering drospirenone with ethinyl estradiol.
- Pharmaceutical formulations containing the two active ingredients.
- Tablet regimens using active and inert tablets.
- Method-of-use claims for contraception and related indications.
- Manufacturing and formulation processes, including control of active-ingredient properties.
The strongest economic patents were the core composition and formulation patents. Those rights supported the branded market before generic entry. Method-of-use claims had narrower commercial value because physicians could prescribe generic versions for the same indication once the relevant patents expired or were successfully challenged.
The original estate no longer provides meaningful market-wide exclusion in the United States. Later patents, if any, would need to cover a specific formulation, process, dosage form, or use and could not automatically restore exclusivity for the basic active-ingredient combination.
How many patents currently cover drospirenone and ethinyl estradiol?
No single patent count accurately describes the global estate. Counts vary according to:
- Jurisdiction.
- Whether expired patents are included.
- Whether applications are counted with issued patents.
- Whether patent-family members are consolidated.
- Whether patents cover the molecule, a specific formulation, a manufacturing process, or an indication.
For U.S. commercial purposes, the relevant question is whether an unexpired patent is listed for the specific reference product in the Orange Book. The Orange Book identifies patents submitted by the NDA holder for approved drug products, but it does not provide a complete freedom-to-operate analysis for every generic formulation or manufacturing process (FDA, n.d.-b).
A patent search should distinguish:
| Patent category |
Current commercial relevance |
| Core combination patents |
Generally expired or no longer blocking |
| Original tablet-formulation patents |
Generally expired or commercially bypassed |
| Method-of-use patents |
Limited if generic labels omit protected uses |
| Process patents |
Potentially relevant to a particular manufacturer |
| Later formulation patents |
Relevant only to the claimed product architecture |
| Foreign patents |
Potentially material outside the United States |
What is the Orange Book status of drospirenone and ethinyl estradiol?
The Orange Book contains multiple reference-listed and generic products for drospirenone and ethinyl estradiol. The applicable reference product depends on the strength, dosage regimen, and approved indication.
The Orange Book is most useful for determining:
- Whether an NDA product has listed patents.
- Whether patents have expired.
- Whether a generic applicant may have submitted a Paragraph IV certification.
- Whether a product has pediatric exclusivity or other listed exclusivity.
- Whether a generic is therapeutically equivalent to the reference product.
The combination does not have active new-drug exclusivity comparable to a recently launched small-molecule product. Most commercial activity now occurs through ANDA-approved products and branded generics.
Which companies challenged the patents?
Generic companies challenged the branded estate through Paragraph IV certifications and related patent litigation. The U.S. generic landscape has included major manufacturers such as Teva, Watson/Actavis, Mylan, Lupin, Glenmark, Sandoz and other ANDA sponsors, depending on the specific product and year.
Paragraph IV litigation historically involved disputes over:
- Whether the listed patents were valid.
- Whether the patents were infringed.
- Whether generic formulations fell within the claims.
- Whether the generic applicant’s proposed label induced infringement.
- Whether settlement agreements restricted or permitted early launch.
A Paragraph IV certification is an assertion that a listed patent is invalid, unenforceable, or not infringed. It does not itself establish market entry. Litigation, settlement, FDA approval and any 30-month stay determine the timing of launch under the Hatch-Waxman framework (FDA, n.d.-c).
What patent litigation and settlement agreements affected the market?
The most important litigation period occurred before broad generic entry. Bayer and related entities faced challenges from generic applicants seeking approval for versions of Yasmin or Yaz. The disputes centered on listed patents covering drospirenone-containing contraceptive products.
Settlement agreements in pharmaceutical patent cases can provide a generic company with an agreed launch date before patent expiry. The Federal Trade Commission has reviewed pharmaceutical settlements for potential anticompetitive provisions, including payments or other restrictions on generic entry (Federal Trade Commission, n.d.).
The commercial result was a transition from a protected branded market to a multi-supplier market. Litigation no longer appears to create a broad barrier to generic access to the basic combination in the United States. Product-specific disputes can still arise over manufacturing, labeling, supply, or later-added patents.
What formulations are protected by drospirenone and ethinyl estradiol patents?
The main formulation distinctions are:
- 3 mg drospirenone with 0.03 mg ethinyl estradiol, associated with Yasmin-type products.
- 3 mg drospirenone with 0.02 mg ethinyl estradiol, associated with Yaz-type products.
- 24 active tablets followed by four inert tablets.
- 21 active tablets followed by seven inert tablets.
- Alternative packaging and tablet-color configurations.
Formulation protection has limited value when multiple manufacturers can develop bioequivalent products using different excipients or manufacturing processes. A generic company can often avoid infringement by adopting a non-infringing formulation while meeting the same bioequivalence requirements.
The principal technical barriers are manufacturing consistency, control of drospirenone content, impurity limits, dissolution performance, stability, and reliable production of low-dose tablets. These are regulatory and quality barriers rather than durable market-exclusion rights.
How strong is the patent estate for drospirenone and ethinyl estradiol?
The current patent estate is weak as a barrier to U.S. generic entry because the core product has been commercialized for more than two decades and has multiple approved generic suppliers.
| Factor |
Assessment |
| Core composition protection |
Low current strength |
| Orange Book blocking power |
Low for the basic combination |
| Formulation differentiation |
Moderate only for narrow product claims |
| Method-of-use protection |
Limited and indication-specific |
| Process patent risk |
Manufacturer-specific |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Regulatory complexity |
Moderate |
| Supply-chain risk |
More relevant than patent risk |
Patent strength can still differ in Europe, emerging markets, and countries with different filing dates or enforcement standards. A global assessment must review national patent registers and regulatory approvals separately.
What is the FDA regulatory status?
Drospirenone and ethinyl estradiol products are FDA-approved prescription oral contraceptives. The regulatory pathway differs by product:
- Branded products use an NDA.
- Generic products use an ANDA.
- Therapeutic equivalence depends on FDA product codes and Orange Book ratings.
- Product labeling must reflect the approved indication and formulation.
- Safety labeling addresses thromboembolic risk, cardiovascular contraindications, hyperkalemia risk in susceptible patients, and drug interactions.
Drospirenone has antimineralocorticoid activity, which distinguishes it from some other progestins. The FDA labeling warns about potassium-related risks in patients using medications that can increase serum potassium and identifies contraindications related to thrombotic disease and estrogen exposure (FDA, n.d.-d).
How does drospirenone and ethinyl estradiol compare with competing contraceptives?
The combination competes with several product classes:
| Product class |
Competitive advantage |
Limitation |
| Levonorgestrel/ethinyl estradiol |
Lower-cost, broad generic availability |
Different progestin profile |
| Norgestimate/ethinyl estradiol |
Established contraceptive and acne positioning |
Generic price competition |
| Desogestrel/ethinyl estradiol |
Alternative progestin profile |
Smaller or uneven availability by market |
| Drospirenone-only products |
Estrogen-free option |
Different dosing and clinical positioning |
| Long-acting reversible contraceptives |
High adherence and duration |
Higher upfront cost and procedure requirement |
| Transdermal and vaginal systems |
Non-oral delivery |
Device and tolerability considerations |
Drospirenone-containing products retain commercial differentiation through acne and premenstrual dysphoric disorder indications, patient familiarity and perceived tolerability. Those factors do not eliminate generic substitution.
What is the financial trajectory of the market?
The financial trajectory follows the standard branded-to-generic pattern:
- Branded launch and price premium.
- Growth from contraceptive adoption and expanded indications.
- Patent litigation and delayed generic entry.
- Rapid price erosion after multiple generic launches.
- Mature-market stabilization with low unit prices and recurring demand.
- Continued revenue fragmentation across generic suppliers and branded-generic marketers.
Current product-level revenue cannot be reliably attributed to one company because:
- Yasmin and Yaz sales are not consistently reported as standalone global products.
- Generic revenue is distributed among several manufacturers.
- Some branded-generic products are licensed, acquired, or sold through distributors.
- Public filings typically aggregate oral contraceptives within larger business segments.
- Net sales differ materially by country, payer and channel.
Revenue exposure is therefore more relevant for companies with a broad women’s-health portfolio than for the active ingredients alone. The combination can generate recurring volume but generally lacks the pricing power associated with a protected specialty drug.
What generic launch risks exist?
Generic launch risk is high for any remaining branded product and moderate for new generic entrants.
Risks for branded manufacturers
- Automatic or pharmacy-level substitution.
- Formularies favoring lower-cost alternatives.
- Declining reimbursement.
- Limited ability to extend exclusivity through minor formulation changes.
- Competition from other hormonal contraceptive classes.
- Product shortages or discontinuations affecting brand availability.
Risks for generic manufacturers
- Intense price competition.
- FDA manufacturing-compliance requirements.
- Bioequivalence failure or delayed approval.
- Supply interruptions involving active pharmaceutical ingredients.
- Small commercial margins after several entrants.
- Litigation over process or formulation patents.
The principal barrier is manufacturing economics, not core patent exclusion.
What licensing deals affect drospirenone and ethinyl estradiol?
Commercial rights have historically involved licensing, distribution and authorized-generic structures, but no single current licensing arrangement defines the global market. Rights can differ between:
- The original innovator.
- Generic manufacturers.
- Authorized-generic distributors.
- National marketing authorization holders.
- Retail and institutional distributors.
Licensing analysis should focus on the specific product and country. A license to market a branded generic does not establish ownership of the underlying active ingredients or provide exclusivity against independently approved generics.
Is there biosimilar risk for drospirenone and ethinyl estradiol?
No. Biosimilar risk does not apply because drospirenone and ethinyl estradiol are chemically synthesized small molecules, not biologics.
The relevant competitive threat is generic substitution under the ANDA pathway. Biosimilar concepts such as reference biologics, interchangeability and biologics exclusivity do not govern this market.
What generic entry scenarios remain?
The base case is continued generic availability with stable demand and low pricing.
| Scenario |
Probability profile |
Market effect |
| Continued multi-source supply |
Base case |
Low prices and persistent substitution |
| Manufacturer exit |
Possible |
Temporary shortages and short-term price increases |
| New branded formulation |
Selective |
Niche pricing if clinically differentiated |
| Patent-based reblocking |
Low |
Requires a valid, unexpired narrow patent |
| Regulatory safety change |
Low but material |
Could affect labeling or utilization |
| Distribution consolidation |
Possible |
Changes channel economics more than patent status |
A new formulation could obtain regulatory approval and potentially support a new patent position, but it would compete against an established low-cost market. Commercial success would depend on adherence, delivery format, clinical differentiation, reimbursement and distribution.
Key Takeaways
- Drospirenone and ethinyl estradiol is a mature combined oral contraceptive market.
- Yasmin and Yaz created the principal U.S. branded market, but core exclusivity has expired.
- Generic competition is extensive and is the main driver of pricing.
- Orange Book analysis must be performed by specific strength, dosage regimen and reference product.
- Paragraph IV litigation shaped the timing of generic entry but does not create a current broad barrier.
- Formulation and process patents may remain relevant to individual products, but they do not restore molecule-level exclusivity.
- Biosimilar risk is not applicable; ANDA-based generic substitution is the relevant threat.
- Product-level revenue is fragmented and generally not separately disclosed by public companies.
- Current commercial risk is driven more by price erosion, manufacturing reliability and formulary substitution than by patent expiry.
FAQs
Is Yaz still patent protected?
The original core Yaz patent protection no longer prevents broad U.S. generic competition. Any remaining patent inquiry must be product-specific and verified through the current Orange Book.
Is Nikki the same drug as Yaz?
Nikki is generally a generic version of the 3 mg drospirenone and 0.02 mg ethinyl estradiol combination associated with Yaz-type products. Approved indications, inactive ingredients and packaging can differ.
Can a generic drospirenone and ethinyl estradiol product launch before every patent expires?
A generic applicant can certify that a listed patent is invalid, unenforceable or not infringed through Paragraph IV. Launch timing then depends on litigation, settlement, FDA approval and applicable statutory stays.
Does drospirenone create a unique regulatory risk?
Yes. Its antimineralocorticoid activity creates labeling and patient-selection considerations involving potassium, renal impairment, adrenal disease and interacting medicines. These risks are clinical and regulatory rather than evidence of active market exclusivity.
Will drospirenone and ethinyl estradiol remain commercially attractive?
It is likely to remain commercially relevant through recurring contraceptive demand, but the market is more attractive for efficient generic manufacturers and portfolio distributors than for a company relying on premium pricing for the basic combination.
References
Federal Trade Commission. (n.d.). Pay-for-delay: When drug companies agree not to compete. https://www.ftc.gov/
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.-c). Paragraph IV certification. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-certifications
U.S. Food and Drug Administration. (n.d.-d). Yaz prescribing information. Bayer HealthCare Pharmaceuticals, Inc. https://labeling.bayerhealthcare.com/html/products/pi/fhc/YAZ_PI.pdf
